Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fulvestrant intraductal - Atossa Therapeutics

Next Previous
Search
Drug Profile

Fulvestrant intraductal - Atossa Therapeutics

Alternative Names: Fulvestrant - Atossa Therapeutics

Latest Information Update: 16 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atossa Genetics
  • Developer Atossa Therapeutics
  • Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Small molecules; Sulfoxides
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 14 Oct 2021 Discontinued - Phase-II for Breast cancer (Neoadjuvant therapy) in USA (Parenteral) (Atossa Therapeutics pipeline, October 2021)
  • 18 Aug 2020 Atossa terminated the '007' phase II trial in Breast cancer (Neoadjuvant therapy) in USA, due to business decision (NCT02540330)
  • 02 Mar 2016 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy) in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top